Jia Liu: Thrilled to share results from the Phase I/II clinical trial of dendrimer SN38
Jia Liu, Translational Lead, Early Phase Drug Development at The Kinghorn Cancer Centre and Conjoint Senior Lecture at UNSW, shared a post on LinkedIn:
”Thrilled to have the opportunity to share promising results from the Phase I/II clinical trial of dendrimer SN38 with a global audience at the ASCO24 Annual Meeting on behalf of co-investigators and Starpharma.
We showed in an FIH Phase I/II clinical trial that successfully recruited during/post COVID-19 pandemic, with 114 patients dosed across 5 sites in Australia and United Kingdom:
- DEP-SN38 is well tolerated with very low rates of gastrointestinal toxicity and no cholinergic reactions and does not require atropine premedication.
- Promising efficacy signals in irinotecan pre-treated colorectal cancer and platinum resistant/refractory ovarian cancer with prolonged tolerability and affording good quality of life for patients on trial.
- Dendrimer technology has the opportunity to deliver a range of payloads including radio-isotopes and ADCs.
Gratitude to all patients, carers, site support staff, referring clinicians and co-investigators for making this trial possible.
Thank you Stephanie Edmondson and Jeremy Paull for weeks of hard work pulling all the data together and bearing with my multiple revisions of the slides to make the presentation clear and easy to understand (a pet passion of mine)…
Look forward to seeing further investigator-led collaborations and pharma partnerships utilising dendrimer platforms come to fruition in the coming months.”
Source: Jia Liu/LinkedIn
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023